Assessment and characterization of gut microbiota has become a major research area in human disease, including type 2 diabetes, the most prevalent endocrine disease worldwide. To carry out analysis on gut microbial content in patients with type 2 diabetes, we developed a protocol for a metagenome-wide association study (MGWAS) and undertook a two-stage MGWAS based on deep shotgun sequencing of the gut microbial DNA from 345 Chinese individuals. We identified and validated approximately 60,000 type-2-diabetes-associated markers and established the concept of a metagenomic linkage group, enabling taxonomic species-level analyses. MGWAS analysis showed that patients with type 2 diabetes were characterized by a moderate degree of gut microbial dysbiosis, a decrease in the abundance of some universal butyrate-producing bacteria and an increase in various opportunistic pathogens, as well as an enrichment of other microbial functions conferring sulphate reduction and oxidative stress resistance. An analysis of 23 additional individuals demonstrated that these gut microbial markers might be useful for classifying type 2 diabetes.
Access optionsAccess options
Subscribe to Journal
Get full journal access for 1 year
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Sequence Read Archive
The raw Illumina read data of all 368 samples has been deposited in the NCBI Sequence Read Archive under accession numbers SRA045646 and SRA050230. The assembly data, updated metagenome gene catalogue, annotation information, and MGLs are published in the GigaScience database, GigaDB35.
We thank L. Goodman for editing the manuscript and providing comments. This research was supported by the Ministry of Science and Technology of China, 863 program (2012AA02A201), the National Natural Science Foundation of China (30890032, 30725008, 30811130531, 31161130357), the Shenzhen Municipal Government of China (ZYC200903240080A, BGI20100001, CXB201108250096A, CXB201108250098A), the Danish Strategic Research Council grant (2106-07-0021), the Ole Rømer grant from Danish Natural Science Research Council, the Solexa project (272-07-0196), and the European Commission FP7 grant HEALTH-F4-2007-201052. The Lundbeck Foundation Centre for Applied Medical Genomics in Personalised Disease Prediction, Prevention and Care (LuCamp, http://www.lucamp.org). The Novo Nordisk Foundation Center for Basic Metabolic Research is an independent Research Center at the University of Copenhagen partially funded by an unrestricted donation from the Novo Nordisk Foundation (http://www.metabol.ku.dk). We are also indebted to many additional faculty and staff of BGI-Shenzhen who contributed to this work.
This file contains Supplementary Tables 1-14.
About this article
SN Comprehensive Clinical Medicine (2019)